Surmodics Stock Today
SurModics is trading at 42.98 as of the 24th of December 2025; that is No Change since the beginning of the trading day. The stock's open price was 42.98. The performance scores are derived for the period starting the 4th of January 2024 and ending today, the 24th of December 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 4th of March 1998 | Category Healthcare | Classification Health Care |
SurModics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Gary Maharaj | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite Total, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSurModics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand SurModics' financial leverage. It provides some insight into what part of SurModics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SurModics (SRDX) is traded on NASDAQ Exchange in USA and employs 389 people. SurModics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 614.58 M. SurModics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 14.3 M outstanding shares of which 447.4 K shares are at this time shorted by private and institutional investors with about 4.72 trading days to cover.
SurModics currently holds about 22.09 M in cash with 248 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58.
Check SurModics Probability Of Bankruptcy
SurModics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 336.2 K | |
| State Street Corp | 2025-06-30 | 320.9 K | |
| Balyasny Asset Management Llc | 2025-06-30 | 271.7 K | |
| Oddo Bhf Asset Management Sas | 2025-06-30 | 268.1 K | |
| Hsbc Holdings Plc | 2025-06-30 | 266.8 K | |
| Goldman Sachs Group Inc | 2025-06-30 | 229.9 K | |
| Gabelli Securities Inc | 2025-06-30 | 203.6 K | |
| Cnh Partners, Llc | 2025-06-30 | 156.2 K | |
| Millennium Management Llc | 2025-06-30 | 155.6 K | |
| Blackrock Inc | 2025-06-30 | 1.1 M | |
| Alliancebernstein L.p. | 2025-06-30 | 850.5 K |
SurModics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. SurModics market risk premium is the additional return an investor will receive from holding SurModics long position in a well-diversified portfolio.
| Mean Deviation | 1.9 | |||
| Semi Deviation | 1.26 | |||
| Standard Deviation | 6.31 | |||
| Variance | 39.86 |
SurModics Stock Against Markets
SurModics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with SurModics stock to make a market-neutral strategy. Peer analysis of SurModics could also be used in its relative valuation, which is a method of valuing SurModics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
SurModics Corporate Management
| Charles Olson | Sr. VP and General Manager of Medical Device | Profile | |
| Timothy Arens | VP of Corporate Devel. and Strategy | Profile | |
| Joseph Stich | VP and General Manager of In-Vitro Diagnostics | Profile | |
| Gordon JD | General Legal | Profile | |
| Gordon Weber | General Legal | Profile |
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.